Henry Esber, Ph.D.
Chairman of the Board
Esber has been the Chairman of the Board since 2012 and served as a Director since January 2011. He is also the Chairperson of the Compensation Committee and is a member of the Audit and Governance and Nominating Committees. In 2000, Esber co-founded Bio-Quant, Inc. and served as its Senior Vice President as well asChief Business Development Officer for 10 years. He has over 35 years of experience in the pharmaceutical service industry, including tenures as the Executive Director of Business Development at Charles River Laboratories and Director of the Department of Immunology and Clinical Services at TSI Mason. Furthermore, he served on the Board of Directors of Apricus Biosciences, Inc. (NASDAQ: APRI) and currently serves at several privately-held pharmaceutical companies.
Ziad Mirza, M.D.
Mirza has served as a Director since 2010 and was previously the Chairman of the Board. He is the Chairperson of the Governance and Nominating Committee and is a member of the Audit and Compensation Committees. He is also the President and Co-founder of Baltimore Medical and Surgical Associates and currently serves as the Medical Director of six nursing homes in the Baltimore area and as the Medical Director of The Greater Baltimore Medical Center Wound Care and Hyperbaric Unit. Mirza is currently enrolled as an investigator in Stem Cell Research in Diabetic Foot Ulcers, and is double boarded in Internal Medicine, Dive and Hyperbaric Medicine - in 1999, he became a Certified Medical Director of long-term care through the American Medical Directors Association. In 2003, Mirza received accreditation as a Certified Physician Executive from the American College of Physician Executives (ACPE), and in 2007, he obtained his MBA in Health Care from the University of Massachusetts.
Before becoming a Director, Liu served as the President and CEO from 2011 to 2012. She is the Chairperson of the Audit Committee and is a member of the Compensation and Governance and Nominating Committees. In 1995, she co-founded NexMed, Inc., which was renamed Apricus Biosciences, Inc. (NASDAQ: APRI) in 2010, and served as the President and Chief Executive Officer from 2007-2009, after having served in various executive capacities. Liu was appointed to the NexMed Board of Directors in 2007 and served as its Chairman from 2009 to 2010. Prior to co-founding NexMed, she was the Commercial Attaché with the Delegation of Quebec in Los Angeles, responsible for business development projects for the medical, pharmaceutical and biotechnology industries. Liu is currently a partner at OxOnc Development LP, a privately-held oncology development company funded by Orbimed Advisors, and a member of the Board of Directors of Cesca Therapeutics, Inc., (Nasdaq: KOOL), as well.
Bassam Damaj, Ph.D.
Prior to joining Innovus Pharma, Bassam Damaj served as President and Chief Executive Officer of Apricus Biosciences, Inc. (NASDAQ: APRI), a specialty pharmaceutical company where he was responsible for the approval of its lead drug Vitaros™, a treatment for erectile dysfunction. Damaj also signed multimillion-dollar partnerships between Apricus Bio and leading pharmaceutical companies such as Abbott, Novartis-Sandoz and Takeda. He was also a Co-founder of Bio-Quant, Inc., serving as the Chief Executive Officer/Chief Scientific Officer and managing the board of directors from its inception in June 2000 until its 2009 acquisition by Apricus Biosciences. In addition, Damaj was the Founder/Chairman/President/Chief Executive Officer of R&D Healthcare, and the Co-Founder of Celltek Biotechnologies. He also served as a Director of the Board of Directors at CreAgri, Inc. and was part of the Scientific Advisory Board of MicroIslet, Inc. He authored Immunological Reagents and Solutions: A Laboratory Handbook (2000) and won a U.S. Congressional Award for the Anthrax Multiplex Diagnostic Test in 2003. Damaj holds a Ph.D. degree in Immunology/Microbiology from Laval University and completed a postdoctoral fellowship in Molecular Oncology at McGill University.